BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 16869746)

  • 1. p53-Dependent and -independent functions of the Arf tumor suppressor.
    Sherr CJ; Bertwistle D; DEN Besten W; Kuo ML; Sugimoto M; Tago K; Williams RT; Zindy F; Roussel MF
    Cold Spring Harb Symp Quant Biol; 2005; 70():129-37. PubMed ID: 16869746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
    D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
    Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
    Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
    Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus.
    Gilley J; Fried M
    Oncogene; 2001 Nov; 20(50):7447-52. PubMed ID: 11704876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
    Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
    Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
    Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
    Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitination of, and sumoylation by, the Arf tumor suppressor.
    den Besten W; Kuo ML; Tago K; Williams RT; Sherr CJ
    Isr Med Assoc J; 2006 Apr; 8(4):249-51. PubMed ID: 16671360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ARF tumour suppressor.
    Gallagher SJ; Kefford RF; Rizos H
    Int J Biochem Cell Biol; 2006; 38(10):1637-41. PubMed ID: 16600663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
    D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
    Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
    Haviernik P; Schmidt M; Hu X; Wolff L
    Oncogene; 2003 Mar; 22(11):1600-10. PubMed ID: 12642863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
    Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ARF tumor suppressor inhibits BCL6-mediated transcriptional repression.
    Suzuki H; Kurita M; Mizumoto K; Moriyama M; Aiso S; Nishimoto I; Matsuoka M
    Biochem Biophys Res Commun; 2005 Jan; 326(1):242-8. PubMed ID: 15567177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The INK4a/ARF locus and melanoma.
    Sharpless E; Chin L
    Oncogene; 2003 May; 22(20):3092-8. PubMed ID: 12789286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
    Russell JL; Weaks RL; Berton TR; Johnson DG
    Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways.
    Weber HO; Samuel T; Rauch P; Funk JO
    Oncogene; 2002 May; 21(20):3207-12. PubMed ID: 12082636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sumoylation induced by the Arf tumor suppressor: a p53-independent function.
    Tago K; Chiocca S; Sherr CJ
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7689-94. PubMed ID: 15897463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the Arf/p53 tumor surveillance network by E2F.
    Iaquinta PJ; Aslanian A; Lees JA
    Cold Spring Harb Symp Quant Biol; 2005; 70():309-16. PubMed ID: 16869767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation.
    Pérez de Castro I; Benet M; Jiménez M; Alzabin S; Malumbres M; Pellicer A
    Cancer Res; 2005 Apr; 65(8):3249-56. PubMed ID: 15833857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas.
    Ito T; Nishida N; Fukuda Y; Nishimura T; Komeda T; Nakao K
    J Gastroenterol; 2004; 39(4):355-61. PubMed ID: 15168247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype.
    King D; Yang G; Thompson MA; Hiebert SW
    Oncogene; 2002 Jul; 21(32):4978-82. PubMed ID: 12118376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.